Lysosomes and Trivalent Arsenic Treatment in Acute Promyelocytic Leukemia

• Published in: JNCI : Journal of the National Cancer Institute Vol. 99; no. 1; pp. 41 - 52
• Main Authors: Kitareewan, Sutisak, Roebuck, B. D., Demidenko, Eugene, Sloboda, Roger D., Dmitrovsky, Ethan
• Format: Journal Article
• Language: English
• Published: Cary, NC Oxford University Press 03.01.2007; Oxford Publishing Limited (England)
• Subjects: Antineoplastic agents; Antineoplastic Agents - pharmacology; Arsenites - pharmacology; Biological and medical sciences; Caspase 3 - metabolism; Caspase 7 - metabolism; Cathepsin L; Cathepsins - metabolism; Cellular biology; Chemotherapy; Cysteine Endopeptidases - metabolism; Dose-Response Relationship, Drug; Humans; Leukemia; Leukemia, Promyelocytic, Acute - drug therapy; Leukemia, Promyelocytic, Acute - metabolism; Lysosomes - drug effects; Lysosomes - metabolism; Medical sciences; Microscopy, Electron, Transmission; Oncogene Proteins, Fusion - drug effects; Oncogene Proteins, Fusion - metabolism; Oncology; Peptide Hydrolases - metabolism; Pharmacology. Drug treatments; Prescription drugs; Proteins; Research Design; Time Factors; Tumor Cells, Cultured; Tumors; Antineoplastic agent; Human; Promyelocytic leukemia; Chemotherapy; Cancerology; Treatment; Acute; Lysosome; Arsenic trioxide; Malignant hemopathy; Trivalent cation; M3 acute myelocytic leukemia

Background Cells from patients with t(15;17) acute promyelocytic leukemia (APL) express the fusion protein between the promyelocytic leukemia protein and retinoic acid receptor α (PML/RARα). Patients with APL respond to differentiation therapy with all-trans-retinoic acid, which induces PML/RARα deg...